Alpha Teknova (NASDAQ:TKNO) Issues Quarterly Earnings Results

Key Points

• Alpha Teknova reported a quarterly loss of ($0.07) earnings per share, surpassing analysts' expectations of ($0.10), with revenue reaching $10.29 million.
• Shares of Alpha Teknova fell by 2.5% to $4.23 following the earnings announcement, amidst concerns over a significant negative return on equity of 25.98%.
• Geode Capital Management significantly increased its stake in Alpha Teknova by 64.4%, now holding roughly 0.56% of the company’s shares.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03, Zacks reports. Alpha Teknova had a negative return on equity of 26.51% and a negative net margin of 55.24%. The business had revenue of $10.29 million for the quarter, compared to the consensus estimate of $9.90 million. Alpha Teknova updated its FY 2025 guidance to EPS.

Alpha Teknova Stock Down 1.6%

Shares of NASDAQ TKNO traded down $0.08 during mid-day trading on Thursday, reaching $4.80. 390,208 shares of the company were exchanged, compared to its average volume of 329,235. The company has a quick ratio of 4.71, a current ratio of 5.87 and a debt-to-equity ratio of 0.17. The stock has a market cap of $256.85 million, a price-to-earnings ratio of -11.43 and a beta of 0.32. Alpha Teknova has a 1 year low of $3.75 and a 1 year high of $10.37. The firm has a 50-day moving average of $4.98 and a 200 day moving average of $5.97.

Insider Buying and Selling at Alpha Teknova

In related news, Director Martha J. Demski sold 8,000 shares of the company's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $5.06, for a total transaction of $40,480.00. Following the completion of the sale, the director directly owned 12,000 shares in the company, valued at $60,720. This represents a 40.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alpha Teknova

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in shares of Alpha Teknova by 64.4% during the 2nd quarter. Geode Capital Management LLC now owns 298,850 shares of the company's stock worth $1,468,000 after purchasing an additional 117,016 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Alpha Teknova by 68.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company's stock worth $470,000 after purchasing an additional 36,763 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Alpha Teknova by 83.0% during the 2nd quarter. Marshall Wace LLP now owns 90,032 shares of the company's stock worth $442,000 after purchasing an additional 40,825 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Alpha Teknova in the second quarter valued at about $96,000. Finally, JPMorgan Chase & Co. boosted its holdings in Alpha Teknova by 123.1% in the second quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company's stock worth $40,000 after acquiring an additional 4,504 shares in the last quarter. 13.81% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Stephens raised Alpha Teknova to a "strong-buy" rating and set a $8.00 price target on the stock in a research report on Tuesday, July 22nd.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.